Healthcare costs. PBM reform. Drug price controls. FDA stability. American manufacturing.

This week on the Making Medicine Podcast, John Stanford sits down with Charles Crain, Vice President of Domestic Policy at the National Association of Manufacturers, to discuss a new report examining the rising cost of healthcare and its impact on American manufacturers.

Manufacturers provide health coverage to millions of workers, making healthcare affordability a major business concern. But according to NAM, the solution isn't limiting pharmaceutical innovation. Instead, the conversation focuses on PBM reform, 340B program transparency, regulatory certainty, preventative care, and policies that lower costs without undermining America's leadership in medical innovation.

The discussion also explores why FDA stability matters beyond the biotech sector, how regulatory uncertainty affects long-term investment, and what policymakers should prioritize to strengthen American competitiveness in the face of growing global competition. 

This Episode Covers:
🔹 Why healthcare costs are manufacturers' top business concern
🔹Why NAM opposes pharmaceutical price controls
🔹The real drivers of rising healthcare costs
🔹PBM reform and prescription drug transparency
🔹The 340B program and hospital incentives
🔹Why FDA stability matters for innovation
🔹Regulatory certainty and biotech investment
🔹Manufacturing, R&D, and American competitiveness
🔹Lessons from COVID supply chain vulnerabilities
🔹How to compete with China through innovation

At the center of this conversation is a simple question: How do we lower healthcare costs without weakening the innovation ecosystem that develops new medicines? Charles Crain argues that affordability and innovation are not competing goals, and that policymakers should focus on the structural drivers of healthcare spending rather than policies that could reduce future medical breakthroughs.

Check out the NAM report: "Prescription for a Healthy Workforce: Manufacturers' Roadmap to Lower Healthcare Costs"
https://nam.org/issues/health-care/ 

Join the Conversation ⬇️
Are policymakers focusing on the right drivers of healthcare costs?
Should PBM reform be a higher priority than drug price controls?
What matters most for U.S. competitiveness: tax policy, regulatory certainty, or innovation incentives? Let us know your thoughts in the comments below 👇

If you're new to the Making Medicine Podcast, we're happy you're here!
Follow us for more:
X: https://x.com/MakingMedPod 
Instagram: https://www.instagram.com/makingmedicinepod/
TikTok: https://www.tiktok.com/@makingmedicinepodcast?lang=en
LinkedIn: https://www.linkedin.com/showcase/making-medicine-podcast/about/?viewAsMember=true

👍 Like and subscribe for more conversations on FDA policy, biotech investing, healthcare innovation, drug development, gene therapy, AI in medicine, and the future of biotechnology.

Timestamps
00:00 Intro & Disclaimer
00:37 Meet Charles Crain & NAM
01:03 Why Manufacturers Care About Healthcare Costs
03:24 Why Healthcare Costs Keep Rising
05:57 What NAM Would Do to Lower Costs
08:03 Why Manufacturers Oppose Drug Price Controls
09:20 The Innovation Tradeoff Explained
10:54 Understanding the 340B Program
13:16 PBMs & Healthcare Middlemen
15:09 How Powerful Are PBMs?
17:13 Why FDA Stability Matters
18:16 Regulatory Costs & Uncertainty
19:30 Why Biotech Needs Predictable Rules
20:43 Building Bipartisan Policy Solutions
23:18 Competing With China Through Innovation
25:12 Final Thoughts

DISCLAIMER: We’re reporting on the headlines, not making medical recommendations. For personal health questions, always consult a doctor.

#healthcarepolicy #pbm #biotech #drugpricing #fda #manufacturing #makingmedicine

China and biotech competition. Drug pricing reform. The FDA. PBMs. America’s innovation economy.

This week on the Making Medicine Podcast, John Stanford sits down with Rep. Scott Peters to discuss the future of American biotech innovation, the importance of ending the “pill penalty,” and why China’s rapid rise in biotechnology is becoming a major strategic concern for the United States.

Representing one of the country’s leading biotech hubs in San Diego, Congressman Peters explains why policies tied to the Inflation Reduction Act and investment incentives directly impact whether innovative medicines get funded, developed, and brought to patients.

The conversation also explores the future of PBM reform, rare disease investment, FDA modernization, the workforce and scientific talent, supply chain security, and what policymakers must do to keep America competitive in biotech and life sciences innovation.

This episode covers:
🔹 Why San Diego became a biotech powerhouse
🔹 The “pill penalty” and the EPIC Act
🔹 How the IRA changed biotech investment incentives
🔹 Why rare disease investment rebounded after the ORPHAN Cures Act
🔹 China’s growing role in global biotech innovation
🔹 FDA modernization and regulatory competitiveness
🔹 Immigration, talent, and scientific leadership
🔹 PBM reform and healthcare affordability
🔹 Why diagnostics and genomics may transform healthcare
🔹 The importance of bipartisan problem-solving in healthcare policy

At the center of the discussion is one core issue: competitiveness. Congressman Peters argues that America’s advantage in biotech depends on stable investment incentives, strong scientific institutions, private-sector innovation, and policies that continue attracting talent and capital into the United States.

Check out more from Incubate Coalition:
https://www.incubatecoalition.org/

Join the Conversation ⬇️
Do you think the United States is doing enough to stay competitive with China in biotech innovation? Should Congress further reform the IRA to encourage more biotech investment and drug development?
What matters most for the future of American healthcare innovation: FDA modernization, PBM reform, or stronger investment incentives?
Let us know your thoughts in the comments below 👇

If you're new to the Making Medicine Podcast, we're happy you're here! Follow us for more:
X: https://x.com/MakingMedPod
Instagram: https://www.instagram.com/makingmedicinepod/
TikTok: https://www.tiktok.com/@makingmedicinepodcast?lang=en
LinkedIn: https://www.linkedin.com/showcase/making-medicine-podcast/about/?viewAsMember=true

👍 Like and subscribe for more conversations on FDA policy, biotech investing, healthcare innovation, drug development, gene therapy, AI in medicine, and the future of biotechnology.

Timestamps
00:00 Intro & Disclaimer
00:17 Why China Is Catching Up in Biotech
00:31 Meet Congressman Scott Peters
01:28 Why San Diego Became a Biotech Hub
03:24 The Role of NIH & Research Institutions
05:02 Venture Capital & Biotech Growth
07:06 The “Pill Penalty” Explained 
08:05 The IRA & Medicare Drug Negotiation
09:25 Why Investment Incentives Matter
11:11 How Small Molecule Investment Was Affected
12:20 Political Risks of Supporting Biotech
15:17 Why Independence Still Matters in Congress
21:26 Rare Disease Investment & Orphan Cures Act
24:00 China’s Rise in Biotech Innovation
25:27 FDA Challenges & Global Competition
27:19 Immigration, Talent & Scientific Leadership
30:25 PBM Reform & Healthcare Costs 33:19 Diagnostics, Genomics & Preventive Medicine
34:19 Why Congress Needs Better Biotech Education
36:35 Closing Thoughts

DISCLAIMER: We’re reporting on the headlines, not making medical recommendations. For personal health questions, always consult a doctor.

#fda #biotech #drugpricing #china #pbm #healthcarepolicy #innovation

What does the FDA actually look like on the inside — and why does its structure matter for drug approvals, rare disease therapies, and biotech investment?

This week on the Making Medicine Podcast, host John Stanford is joined by Jef Akst, senior editor at BioSpace, to break down the FDA's key divisions, what each one is responsible for, and how they shape the drug development landscape.

Jef walks through the roles of CDER (Center for Drug Evaluation and Research) and CBER (Center for Biologics Evaluation and Research) — what each center oversees, how they differ, and why their review processes matter to biotech companies navigating approval timelines. The episode also explains how FDA advisory committees work, what authority they hold, and how their recommendations influence regulatory outcomes.

The conversation then expands to the broader policy environment shaping biotech today — including CMS marketplace rule changes that affect patient cost exposure, Section 232 pharmaceutical tariff procedures, Most Favored Nation pricing, and the Orphan Cures Act.

The episode closes with data from the INCUBATE Coalition's biotech investment tracker, examining how IRA policy and regulatory uncertainty are influencing capital allocation across the life sciences sector.

Check out the full report from Manatt Health
https://www.incubatecoalition.org/post/one-pager-complete-report-regulatory-instability-at-fda-is-reshaping-biotech-investment

Check out INCUBATE'S biotech investment tracker
https://lifesciencetracker.com/

Join the Conversation ⬇️
Do you think FDA leadership turnover is creating too much uncertainty for biotech companies and investors?
Should the FDA rely more heavily on advisory committees and outside scientific experts during periods of instability?
How should policymakers balance lower healthcare premiums with the risk of higher out-of-pocket costs for patients?
Let us know your thoughts in the comments below 👇

If you're new to the Making Medicine Podcast, we're happy you're here! Follow us for more: 
X: https://x.com/MakingMedPod
Instagram: https://www.instagram.com/makingmedicinepod/
TikTok: https://www.tiktok.com/@makingmedicinepodcast?lang=en
LinkedIn: https://www.linkedin.com/showcase/making-medicine-podcast/about/?viewAsMember=true

👍 Like, follow, and subscribe for more conversations on FDA policy, biotech innovation, healthcare regulation, drug pricing, rare disease development, and life sciences investment.

Time Stamps
00:00 Intro & Disclaimer
00:17 FDA Instability & Biotech Uncertainty
00:39 Meet BioSpace’s Jef Akst
01:51 FDA, HHS & RFK Jr. Influence
04:13 What CDER Does
05:55 Drug Delays & FDA Inconsistency
07:23 What CBER Does
10:33 Office of Therapeutic Products Turnover
13:08 FDA Commissioner’s Role Explained
15:17 Advisory Committees & Expert Panels
18:00 CMS ACA Rule Changes
19:24 Pharma Tariffs & MFN Pricing
21:06 Senator Bill Cassidy’s Primary Loss
22:50 New Biotech Investment Tracker Data
24:41 Rare Disease Investment Trends
25:17 Closing Thoughts

DISCLAIMER: We’re reporting on the headlines, not making medical recommendations. For personal health questions, always consult a doctor.

#FDA #Biotech #HealthcarePolicy #DrugDevelopment #RareDisease #CMS #Pharma #LifeSciences #MFN #MakingMedicine

FDA instability. AI in clinical trials. China overtaking the United States in biotech development.

Following news that Marty Makary has stepped down as FDA commissioner, questions around regulatory stability, scientific leadership, and the future of biotech innovation are back in focus.

This week on the Making Medicine Podcast, John Stanford examines what the FDA needs most during periods of leadership transition: scientific credibility, regulatory expertise, and a stable, predictable process for developing new medicines.

Recorded before the latest leadership announcement, this episode focuses less on personalities and more on the broader institutional questions shaping the future of drug development, clinical trials, AI-enabled regulation, rare disease research, and America’s global competitiveness in biotech.

This episode covers:  

This episode covers:

🔹 What Marty Makary’s departure could mean for the FDA
🔹 Why FDA stability matters for biotech investment
🔹 The qualities that define effective FDA leadership
🔹 AI, clinical trials, and the future of drug development
🔹 FDA modernization and new approach methodologies
🔹 Rare disease development and regulatory predictability
🔹 Why global biotech competition is accelerating
🔹 How FDA credibility impacts patients, investors, and innovation

At the center of the conversation is one core issue: confidence. Confidence that the FDA remains a science-driven institution capable of supporting innovation while ensuring drugs are safe and effective for American patients. Because uncertainty at the agency doesn’t just affect markets — it affects clinical timelines, capital allocation, and ultimately whether treatments reach patients.

Join the Conversation ⬇️
Do you think the FDA is becoming less predictable?
Should AI play a larger role in clinical trials?
Can America maintain its leadership in biotech innovation?
Let us know your thoughts in the comments below 👇

If you're new to the Making Medicine Podcast, we're happy you're
here! Follow us for more:

https://x.com/MakingMedPod
https://www.instagram.com/makingmedicinepod/
https://www.linkedin.com/showcase/making-medicine-podcast/about/?viewAsMember=true
https://www.tiktok.com/@makingmedicinepodcast?lang=en

👍 Like and subscribe for more conversations on FDA policy, biotech investing, healthcare innovation, drug development, gene therapy, AI in medicine, and the future of biotechnology.

Timestamps
00:00 Intro & Disclaimer
00:33 Why FDA Leadership Matters
01:00 FDA Leadership Shakeup Explained
01:50 Why FDA Stability Impacts Biotech
02:14 The Cost Of Regulatory Uncertainty
02:59 The Three Qualities Of A Strong FDA Commissioner
03:51 Why Regulatory Experience Matters
04:40 AI & The Future Of Clinical Trials
05:47 America’s Healthcare Data Problem
06:17 Why The FDA Must Lead On AI
06:41 The Limits Of FDA Authority
07:07 Why Investors Need Predictability
07:33 FDA Modernization & Innovation
07:55 Why This Matters For Patients
08:21 Rare Disease Patients & FDA Stability
08:41 Passage Bio’s FDA Setback
09:27 China Surpasses The U.S. In Drug Trials
10:09 What The Industry Wants From The FDA
10:32 Why Stable Regulation Matters

DISCLAIMER: We’re reporting on the headlines, not making medical recommendations. For personal health questions, always consult a doctor.

#FDA #Biotech #AI #ClinicalTrials #HealthcarePolicy #RareDisease #GeneTherapy #DrugDevelopment #China #MakingMedicine

Gene therapy breakthroughs. The first oral GLP-1 pill. A troubling signal for scientific talent. And a German pricing move that could quietly reshape global drug development.

This week on the Making Medicine podcast, John Stanford breaks down four stories shaping the future of life sciences and biotech investment. From the FDA's landmark approval of Regeneron's gene therapy for genetic hearing loss to new survey data showing immigration policy is already influencing where top researchers choose to build their careers — the pressure on the innovation ecosystem is building from multiple directions at once.

This episode covers:
🔹 FDA Approvals Corner: Eli Lilly's Foundayo (first oral small-molecule GLP-1 for weight management), Regeneron's Otarmeni (gene therapy for genetic hearing loss), and Merck's Idvynso (once-daily HIV treatment).
🔹 Immigration policy and what a new STAT News survey says about the research pipeline.
🔹 Germany's drug discount proposal and why it complicates the U.S. Most Favored Nation pricing strategy.

At the center of all these conversations is one critical question: can the United States maintain the confidence, in its regulators, its talent pipeline, and its pricing environment, that keeps the biomedical innovation engine running?

Check out the full STAT News Report
https://www.statnews.com/2026/05/04/trump-immigration-policy-stat-survey-measures-science-impact/

Join the Conversation ⬇️
Do you think the FDA is becoming less predictable?
Should the US rethink its MFN drug pricing strategy?
Can America maintain its leadership in biotech innovation?
Let us know your thoughts in the comments below 👇

If you're new to the Making Medicine Podcast, we're happy you're here! Follow us for more: https://x.com/MakingMedPod https://www.instagram.com/makingmedicinepod/ https://www.linkedin.com/showcase/making-medicine-podcast/about/?viewAsMember=true

👍 Like and subscribe for more conversations on FDA policy, biotech investment, drug pricing, healthcare innovation, China competition, and national security.

Time Stamps
00:00 Intro & Disclaimer
00:17 Innovation Ecosystem Runs on Confidence
00:33 FDA, Germany & Biotech Headlines Preview
01:18 FDA Drug Approvals Roundup
01:41 Eli Lilly’s Oral GLP-1 Approval
02:16 Regeneron Gene Therapy Breakthrough
03:18 Immigration Policy & Scientific Talent Concerns
04:56 Germany Challenges MFN Drug Pricing
05:57 Why Global Drug Pricing Could Reshape Launch Strategy
06:49 Rare Disease Investment Risks
07:12 Germany vs Trump MFN Policy
08:08 Why Biotech Innovation Depends on Confidence

DISCLAIMER: We’re reporting on the headlines, not making medical recommendations. For personal health questions, always consult a doctor.

#fda #biotech #drugpricing #glp1 #healthcarepolicy #mfn #germany #regeneron #EliLilly #MakingMedicine

Biotech is no longer just about medicine. It is now a frontline issue in national security, global competition, and economic independence.

In this episode of the Making Medicine Podcast, Senator Todd Young joins us to break down the growing risks of relying on China for critical biotech inputs, why FDA speed and regulatory clarity matter more than ever, and how the US can stay competitive in a rapidly shifting global landscape.

From supply chain vulnerabilities to AI-driven drug development, this conversation explores the intersection of policy, innovation, and national defense. Senator Young also shares insights on drug pricing, biotech investment, and why strengthening the full ecosystem from startups to large manufacturers is critical for long-term US leadership.

If the US fails to act, the consequences go far beyond healthcare. They shape who leads the next century of innovation.

At stake is not just faster cures, but whether America remains the global leader in biotech or falls behind.

Join the Conversation ⬇️
Should the US decouple biotech supply chains from China?
Can the FDA move faster without sacrificing safety?
What policy change would most strengthen US biotech leadership?
Drop your thoughts in the comments below 👇

If you're new to the Making Medicine Podcast, we're happy you're here!
Follow us for more:
https://x.com/MakingMedPod
https://www.instagram.com/makingmedicinepod/
https://www.linkedin.com/showcase/making-medicine-podcast/about/?viewAsMember=true

Time Stamps
00:00 Intro and disclaimer
00:17 Senator Young on China dependency risk
00:33 Meet Senator Todd Young
01:53 Why biotech is national security
03:23 Biotech’s role in defense, materials, and Department of War
04:17 Supply chain resiliency and China risk
05:16 Biotech threats, food security, and countermeasures
06:41 China, biotech standards, and global competition
08:04 Why innovators go abroad for speed and cost
08:46 FDA optimization, AI, and faster drug development
12:16 Indiana’s biotech ecosystem and Eli Lilly
16:32 Why small biotech and big pharma need each other

DISCLAIMER: We’re reporting on the headlines, not making medical recommendations. For personal health questions, always consult a doctor.

#biotech #FDA #China #nationalsecurity #pharma #healthpolicy #innovation #senatortoddyoung

FDA instability is reshaping biotech investment decisions in real time. Investors are recalibrating risk, pulling back, and even shifting capital abroad.

In this episode of the Making Medicine Podcast, John Stanford is joined by Rachel Sher of Manatt Health to unpack new original research conducted with investors across the biotech ecosystem. The goal was simple: move beyond speculation and understand whether recent leadership changes, staffing cuts, and policy uncertainty at FDA are actually shaping investor behavior.

What emerged is a clear signal. Across venture capital, public equity, private equity, and industry investors, the vast majority said recent changes at FDA have altered how they think about risk, capital allocation, and the attractiveness of U.S.-based drug development.

This conversation walks through the four major themes that surfaced in the research: growing concern about regulatory instability, reduced appetite for certain product categories like gene therapy and vaccines, increasing attention to China and other international markets, and broader concern that instability across agencies like NIH and FDA could weaken the long-term innovation pipeline.

At the center of it all is one core issue: regulatory predictability. When investors lose confidence in consistency, policy clarity, and institutional knowledge, the consequences extend far beyond individual companies. They affect portfolios, research priorities, and where innovation happens next.

This episode also highlights something important. Even with all these concerns, investors still want to back innovation in the United States. The question is whether policymakers and regulators can restore the stability and trust that made the U.S. the global leader in biotech in the first place.

Watch for a grounded conversation on what investors are really saying, what it means for the biotech ecosystem, and why FDA predictability matters more than ever.

Check out the full report
https://www.incubatecoalition.org/post/one-pager-complete-report-regulatory-instability-at-fda-is-reshaping-biotech-investment

Join the Conversation ⬇️
Do you think FDA instability is already changing the future of biotech investment? 
Are investors right to look abroad when U.S. regulatory signals become less predictable?
What matters more right now: speed, stability, or scientific consistency?
Drop your thoughts in the comments below 👇

If you're new to the Making Medicine Podcast, we're happy you're here! Follow us for more:  https://x.com/MakingMedPod
https://www.instagram.com/makingmedicinepod/
https://www.linkedin.com/showcase/making-medicine-podcast/about/?viewAsMember=true

Time Stamps
00:00 Intro & Disclaimer
00:16  Investors Say FDA Changes Are Impacting Decisions
03:22 How We Surveyed Investors (Research Design)
07:27 Theme 1: FDA Instability & Investor Uncertainty
10:22 Investors Repricing Risk in Biotech
12:05  “Chaos Is the Only Thing” – Investor Quote
13:00  Theme 2: Pullback from Gene Therapy, Vaccines, Oncology
14:28  Theme 3: Capital Shifting Abroad (China & Competition)
17:02 Theme 4: NIH Cuts & Long-Term Innovation Risk
 25:24 Key Takeaway: Regulatory Predictability Drives Investment

DISCLAIMER: We’re reporting on the headlines, not making medical recommendations. For personal health questions, always consult a doctor.

 #Biotech #FDA #BiotechInvesting #HealthcarePolicy #DrugDevelopment

FDA signals are starting to break down, and biotech is feeling it. One company is collapsing while another is breaking through.

As lawmakers return to Washington for a packed schedule of healthcare hearings, the conversation will be shaped by what’s happening inside the biotech ecosystem right now, both the breakthroughs and the breakdowns.

In this episode of Making Medicine, we connect the dots between what’s unfolding on Capitol Hill and what companies are experiencing on the ground.

We start with the policy backdrop: multiple hearings across the House and Senate, including appearances by HHS Secretary RFK Jr. and a renewed focus on drug pricing, FDA oversight, and the future of biomedical innovation.

Then we turn to two stories that highlight what’s at stake.

On one side is Replimune, a biotech facing layoffs and a collapsing market response after repeated FDA rejections and what leadership described as inconsistent communication and a slow-moving regulatory process.

On the other is Revolution Medicines, whose pancreatic cancer drug is delivering unprecedented clinical results and offering real hope to patients, a powerful example of what the innovation ecosystem looks like when it works.

Together, these stories raise a critical question: Can companies and investors still rely on FDA signals?

Because when those signals become unpredictable, capital pulls back, risk tolerance shrinks, and fewer breakthrough therapies get funded.

We also explore how early-stage investors rely on regulatory clarity, how large pharma acquisitions are helping fuel the biotech ecosystem, and why Congress plays a critical role in shaping what comes next.

The takeaway is simple: Biotech doesn’t succeed or fail in isolation. Policy, regulation, and capital all move together.

Join the Conversation ⬇️
Are we creating a system that rewards safe, incremental drugs over true breakthroughs? If FDA decisions feel unpredictable, does capital move elsewhere, or does innovation slow down entirely?
Drop your thoughts in the comments below 👇

If you're new to the Making Medicine Podcast, we're happy you're here! Follow us for more:  https://x.com/MakingMedPod
https://www.instagram.com/makingmedicinepod/
https://www.linkedin.com/showcase/making-medicine-podcast/about/?viewAsMember=true

Time Stamps
00:00 Intro + Why Biotech Policy Matters Right Now
00:38 Congress Returns: RFK Jr., Drug Pricing, and Key Hearings
03:29 When FDA Delays Kill Companies (Kezar Case)
04:01 Replimune Collapse: From Breakthrough to Rejection
05:46 The Real Risk: Can Investors Trust FDA Signals?
06:51 Revolution Medicines: A Cancer Breakthrough
07:49 Historic Results: First Survival Gains in Pancreatic Cancer
08:22 How Biotech Actually Works (Startups → Pharma)
09:56 Why Big Pharma Deals Matter for Patients
10:06 Collapse vs Breakthrough: Which Future Are We Heading Toward?
10:22 What Congress and FDA Need to Fix
10:50 Faster Drug Development? New FDA Pathway Explained
12:25 Final Take: The Stakes for U.S. Biotech Leadership

DISCLAIMER: We’re reporting on the headlines, not making medical recommendations. For personal health questions, always consult a doctor.

#Biotech #FDA #DrugDevelopment #HealthcarePolicy #BiotechInvesting

Tariffs, MFN pricing, and FDA delays are colliding, and small biotech is paying the price. One company already collapsed. More could follow.

In this episode, we break down how Section 232 pharmaceutical tariffs, the push to codify Most Favored Nation (MFN) pricing, and new proposals in the FDA budget are reshaping biotech in real time.

The stakes are high. These policies don’t just exist on paper, they directly impact where drugs are developed, how capital flows, and whether small biotech companies survive.

We explore how tariffs could strain supply chains and smaller companies, how MFN could change global pricing and investment behavior, and how a proposed expedited IND pathway could help keep early-stage drug development in the United States.

But the biggest signal comes from a real-world example: Kezar Life Sciences, a biotech that shut down after FDA delays disrupted its timeline and investor support.

This episode makes one thing clear: policy is now one of the biggest drivers of innovation or failure in biotech.

When the system works, it accelerates breakthroughs. When it doesn’t, it pushes capital, companies, and science elsewhere.

Join the Conversation ⬇️

Are U.S. biotech policies slowing down the industry more than global competitors like China?
If a company shuts down because of regulatory delays, is that a policy failure or just the cost of doing business?
Would you accept higher risk in early drug development if it meant faster innovation and more breakthroughs?
Drop your thoughts in the comments below 👇

If you're new to the Making Medicine Podcast, we're happy you're here! Follow us for more:  https://x.com/MakingMedPod
https://www.instagram.com/makingmedicinepod/
https://www.linkedin.com/showcase/making-medicine-podcast/about/?viewAsMember=true

Time Stamps
0:00 Episode Introduction
1:36 Section 232 Pharma Tariffs Explained
2:47 Onshoring, MFN Deals, & Exemptions
4:57 The Impact on Small Biotechs & VC
8:17 Why Codifying MFN is Dangerous
9:56 Promising FDA Budget Proposals
11:32 Expedited INDs to Keep Trials in the US
15:49 The Fatal Cost of FDA Delays
17:52 Proposed NIH Budget Cuts & Grant Changes
20:45 The Big Disconnect in Biotech Policy

DISCLAIMER: We’re reporting on the headlines, not making medical recommendations. For personal health questions, always consult a doctor.

#biotechpolicy #fda #drugdevelopment #healthcarepolicy #china #BiotechInnovation

Last week, seven leading life sciences investors went to Washington. They met with the National Security Commission on Emerging Biotechnology, walked the halls of Congress, and shared which roadblocks are preventing them from being a part of the next breakthrough. 
John Gutierrez was one of those investors — and the throughline of nearly every room he walked into was China.

Not as a future threat to get ahead of. But as a current competitor that is already having a real impact on how capital decisions are made and exposing just how much American biotech policy is working against itself.

On this episode, John breaks down what policymakers are missing and what investors are actually seeing: drug pricing proposals that undermine early-stage innovation, an FDA uncertainty gap that large companies can absorb and small companies can't, and a China that is building a cheaper, faster, better-funded competitor while Washington debates the wrong questions.

The U.S. still has the best life sciences ecosystem in the world. Whether that stays true depends on decisions being made right now, and whether the people making them understand what's actually at stake.

This is that conversation. 

Join the Conversation ⬇️
What do you think is the biggest risk to U.S. biotech leadership right now?
Is policy helping or hurting innovation in this moment?
Drop your thoughts in the comments below 👇

If you're new to the Making Medicine Podcast, we're happy you're here! Follow us for more: https://x.com/MakingMedPod
https://www.instagram.com/makingmedicinepod/
https://www.linkedin.com/showcase/making-medicine-podcast/about/?viewAsMember=true

Timestamps
00:00 Disclaimer and opening context
00:37 Capitol Hill biotech roundtable with NSCEB
01:25 Meet investor John Gutierrez and Ascend to Capital
02:15 How biotech investors build and scale companies
03:13 The rise of new biotech hubs like Florida
04:58 Why investors are stepping into policy debates
06:29 Biotech as a national security priority
08:31 Is the U.S. losing biotech leadership to China?
10:30 Competing with China vs trying to contain it
11:06 Why innovation is becoming incremental not transformational
13:43 “Tell me the incentive” how policy drives investor behavior
15:01 The pill penalty and shift away from small molecule drugs
17:04 Policy silos vs the real global biotech competition
18:42 Inside Capitol Hill conversations and policy blind spots
21:26 How global pharma deals fund biotech innovation
23:56 Closing thoughts on U.S. biotech leadership

DISCLAIMER: We’re reporting on the headlines, not making medical recommendations. For personal health questions, always consult a doctor.

#biotech #biotechpolicy #nationalsecurity #biotechinnovation #chinabiotech